Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) is scheduled to be releasing its earnings data after the market closes on Wednesday, August 2nd. Analysts expect Aquinox Pharmaceuticals to post earnings of ($0.51) per share for the quarter.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Tuesday, May 9th. The company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.15. During the same period last year, the business earned ($0.39) EPS. On average, analysts expect Aquinox Pharmaceuticals to post $-2.05 EPS for the current fiscal year and $-2.14 EPS for the next fiscal year.

Shares of Aquinox Pharmaceuticals, Inc. (AQXP) opened at 14.58 on Wednesday. The firm’s market capitalization is $341.51 million. Aquinox Pharmaceuticals, Inc. has a 12 month low of $7.44 and a 12 month high of $19.97. The firm’s 50-day moving average price is $14.25 and its 200-day moving average price is $15.77.

AQXP has been the subject of a number of recent analyst reports. ValuEngine upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cantor Fitzgerald set a $28.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 9th. Finally, Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $19.80.

In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $13.26, for a total value of $207,187.50. Following the completion of the transaction, the insider now directly owns 77,530 shares of the company’s stock, valued at $1,028,047.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.70% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.